Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOFDRA vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Treatment of cataplexy in patients with narcolepsy,Treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Terminal elimination half-life is 6-9 hours in healthy adults; may be prolonged up to 12-15 hours in patients with hepatic impairment.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Sodium oxybate is primarily metabolized by the enzyme GHB dehydrogenase (a form of aldehyde dehydrogenase) and to a minor extent via CYP450 (not a major pathway). Metabolism is saturable and follows first-order kinetics at therapeutic doses.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% excreted unchanged in urine; biliary/fecal elimination accounts for approximately 20% of total clearance.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Approximately 95% bound to albumin and alpha-1-acid glycoprotein.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive extravascular distribution.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral bioavailability is approximately 75% due to first-pass metabolism; intravenous bioavailability is 100%.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No dosage adjustment required for renal impairment.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No dosage adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy in pediatric patients have not been established.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
No dosage adjustment required; systemic exposure is similar to that in younger adults.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and RISK OF ABUSE. SOFDRA is a CNS depressant and can cause respiratory depression, hypotension, profound sedation, coma, and death. Concomitant use of alcohol or other CNS depressants increases these risks. SOFDRA is a Schedule III controlled substance with potential for abuse and dependence.
There is no FDA black box warning for ALPHACAINE.
Central nervous system depression and respiratory depression,Risk of abuse and dependence (Schedule III controlled substance),Sodium content (high sodium intake may be problematic in patients with hypertension, heart failure, or renal impairment),Suicidal ideation and depression (monitor for psychiatric symptoms),Parasomnias (sleepwalking, confusional arousals),Requires strict adherence to dosing schedule (twice nightly, taken at bed and 2.5-4 hours later)
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Concomitant use of alcohol or other CNS depressants (e.g., benzodiazepines, opioids),Succinic semialdehyde dehydrogenase deficiency,Severe hepatic impairment (Child-Pugh C),History of substance abuse (relative contraindication)
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No significant food interactions; take with or without food. Avoid grapefruit juice? Not clinically significant for SOFDRA.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended human dose; however, anticholinergic drugs may cause fetal tachycardia and reduced fetal heart rate variability. Use in pregnancy should be avoided unless clearly needed. First trimester: limited data; no known major malformations. Second and third trimesters: potential for fetal anticholinergic effects, including decreased fetal movement and heart rate variability.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Because of the potential for serious adverse reactions (e.g., anticholinergic effects, including constipation and urinary retention) in breastfeeding infants, breastfeeding is not recommended during treatment with sofdr A. M/P ratio unknown.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data in pregnant women. However, consider potential altered absorption and clearance; use lowest effective dose if required. Monitor for increased anticholinergic adverse effects due to possible changes in metabolism.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
SOFDRA (sofosbuvir 400mg/velpatasvir 100mg) is a pangenotypic NS5B polymerase inhibitor/NS5A inhibitor combination for chronic hepatitis C. Avoid coadministration with strong P-gp inducers (e.g., rifampin, carbamazepine, St. John's wort) which reduce sofosbuvir levels. Monitor for bradycardia when used with amiodarone; consider alternative antiarrhythmic. Dose adjustment not required for mild-moderate renal impairment, but not recommended for severe renal impairment (e GFR <30 m L/min). Test for HBV coinfection prior to initiation; HBV reactivation can occur during and after treatment. Duration: 12 weeks for treatment-naïve or peginterferon/ribavirin-experienced without cirrhosis or with compensated cirrhosis; 24 weeks with ribavirin for decompensated cirrhosis (Child-Pugh B/C). Check sustained virologic response (SVR) at 12 weeks post-treatment.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Take exactly as prescribed; do not skip doses or stop early without consulting your doctor.,If you have hepatitis B, treatment may reactivate the virus; your doctor will monitor you.,Report any signs of severe bradycardia (fainting, dizziness, chest pain) especially if you take amiodarone.,Avoid St. John's wort, rifampin, and carbamazepine during treatment.,Take with or without food; swallow tablet whole.,Complete full course to achieve cure; missed doses should be taken as soon as remembered unless near next dose.,Use effective contraception during and for 6 months after if partner is of childbearing potential; if used with ribavirin, both partners must use two forms of contraception.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOFDRA vs ALPHACAINE, answered by our medical review team.
SOFDRA is a Stimulant Laxative that works by SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOFDRA and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOFDRA is: 1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOFDRA and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOFDRA is classified as Category C. Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended h. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.